Transporter- and enzyme-targeted prodrugs for improved oral drug delivery

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Prodrugs are bioreversible derivatives of drug molecules designed to overcome pharmaceutical, pharmacokinetic, or pharmacodynamic barriers such as low oral absorption, lack of site-specificity, insufficient chemical stability, poor solubility, toxicity, unacceptable taste/odor, etc. The prodrug approach becomes more and more popular and successful; to date, around 10% of all the world’s marketed medications are prodrugs, 20% of all small molecular medicines approved between 2000 and 2008 were prodrugs, and when focusing on 2008 approved drugs, it emerges that over 30% of them were prodrugs (Huttunen et al., 2011; Stella, 2010).

Original languageEnglish
Title of host publicationDrug Delivery
Subtitle of host publicationAn Integrated Clinical and Engineering Approach
PublisherCRC Press
Pages47-64
Number of pages18
ISBN (Electronic)9781466565951
ISBN (Print)9781466565944
DOIs
StatePublished - 1 Jan 2017

ASJC Scopus subject areas

  • General Medicine
  • Pharmacology, Toxicology and Pharmaceutics (all)

Fingerprint

Dive into the research topics of 'Transporter- and enzyme-targeted prodrugs for improved oral drug delivery'. Together they form a unique fingerprint.

Cite this